HIV Infections Clinical Trial
Official title:
Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
NCT number | NCT04206878 |
Other study ID # | EG0206 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2017 |
Est. completion date | December 31, 2020 |
Verified date | February 2021 |
Source | Elizabeth Glaser Pediatric AIDS Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to assess the feasibility and utility of birth testing using point-of-care (POC) testing in maternity settings in Eswatini.
Status | Completed |
Enrollment | 3316 |
Est. completion date | December 31, 2020 |
Est. primary completion date | July 3, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A to 4 Days |
Eligibility | Inclusion Criteria: - HIV Exposed Infants - Must have been newly born at the study sites or presenting in study sites within 3 days after birth - Tested for HIV using POC EID platform (mother or caregiver agreed to have infant tested) - Health Care Workers (HCWs) - HCWs who have used POC EID for at least three months, at project sites - HCWs that work directly with POC EID services at maternity providing clinical services or operating the platform - HCWs who consent to be interviewed - HCWs able to speak one of the study languages - Laboratory Managers and program leads/focal persons: - National or regional level manager or head of department whose responsibilities include EID - Member of a national technical working group or advisory board member working on EID - National level representative from the MOH - Laboratory managers in the 3 study sites - Participants 18 years and above who consent to be interviewed - Mothers/caregivers: - Mother/caregiver of an HEI who was offered POC EID at birth - Provides consent to participate in the study - Is 18 years or older, or is less than 18 years old but is legally married (and thus legally emancipated) - Speaks one of the study languages Exclusion Criteria: - HEIs: - HEI tested for HIV using conventional EID at projects sites - HEI whose caregivers refuse birth testing - HEI where the clinician deems there is a contra-indication for sample collection for birth testing (e.g. severe hemophilia) - HCWs: - HCWs who work within project sites that do not make use of EID (i.e. HCWs who are not involved directly with EID) - HCWs working in non-project sites - HCWs who are unable to consent or do not speak a study language - Laboratory Managers and program leads/focal persons: - Inability to give consent - Inability to speak study language - Mothers/Caregivers: - Not eligible for POC birth testing services - Not able to consent - Does not speak English or SiSwati |
Country | Name | City | State |
---|---|---|---|
Swaziland | Mbabane Government Hospital, Hlathikhulu Hospital, and Good Shepherd Hospital | Mbabane |
Lead Sponsor | Collaborator |
---|---|
Elizabeth Glaser Pediatric AIDS Foundation | UNITAID |
Swaziland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent of eligible HEI born at or presenting to pilot facilities who receive POC EID testing at birth | Number of eligible HEI born at or presenting to pilot facilities receiving POC EID testing as a proportion of the number of HEI born or presenting to pilot facilities | 24 months | |
Secondary | Percent of tested HEI whose caregivers receive results of the POC EID birth testing | Number of tested HEI whose caregivers receive results of the POC EID birth testing as a proportion of the number of tested HEI | 24 months | |
Secondary | HIV positivity rate among HEI tested at birth | Number of HEI testing HIV positive at birth as a proportion of the number of HEI tested at birth | 24 months | |
Secondary | Number of HIV-infected infants (HII) tested at birth who are started on ART within 2 weeks of the birth test | Number of HII tested at birth started on ART within 2 weeks as a proportion of the number of HII tested at birth | 24 months | |
Secondary | Percent of HEI testing HIV negative at birth who return for testing at 6-8 weeks | Number of HEI testing HIV negative at birth who return for testing at 6-8 weeks as a proportion of the number of HEI testing HIV negative at birth | 24 months | |
Secondary | Percent of HEI who test HIV negative at birth and who test positive at 6-8 weeks | Number of HEI who test HIV negative at birth and who test HIV positive at 6-8 weeks as a proportion of the number of HEI who test HIV negative at birth | 24 months | |
Secondary | Percent of HII testing HIV positive at birth or at 6-8 weeks in care for the first 3 and/or 6 months of life | The number of HII testing HIV positive at birth or at 6-8 weeks in care for the first and/or 6 months of life as a proportion of the number of HII testing HIV positive at birth or at 6-8 week of life | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |